Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Is your patient covered?
Document related concepts
Transcript
Topic Suggestions….Contact: Pharmaceutical Services Division Health and Community Services P.O. Box 8700 St. John’s, NL A1B 4J6 Tel: 729-6507 Fax: 729 -2851 Winter 2010 Is your patient covered? ACCESS PLAN A program that provides up to 80% coverage of eligible prescription drug costs to those with low incomes, even if they have insurance. ASSURANCE PLAN A program that provides assistance to those with high eligible prescription drug costs based on income levels. Patients can call 1-888-859-3535 or visit www.areyoucoverednl.ca to find out if they are eligible. SPECIAL AUTHORIZATION REQUEST FORMS Special Authorization request forms are available on the Department of Health and Community Services website http://www.health.gov.nl.ca/health/forms/index.html#4 in the Forms and Applications section. There is a standard form as well as specialized forms for Cholinesterase Inhibitors, Clopidogrel, Sevelamer, Methadone, Crohn’s Disease medications (anti-TNF agents), Psoriasis and Rheumatoid Arthritis medications. These forms are a good guide as to what information is needed for assessment for coverage and are being regularly updated to reflect NLPDP changes. DOCTOR WHO? Special authorization requests should include the requesting prescriber’s name (printed), license number and contact information. This is helpful for communicating the results of the special authorization assessment including coverage details and any reassessment needed for coverage renewal as well as requesting additional information that may be needed to complete an assessment for coverage. CHANGES TO THE NLPDP BENEFIT LISTING New open benefits for Foundation, 65Plus, Access and Assurance Plans Atacand Plus (candesartan/hydrochlorthiazide) 32mg/12.5mg DIN 02332922 Atacand Plus (candesartan/hydrochlorthiazide) 32mg/25mg DIN 02332957 Coversyl Plus HD (perindopril/indapamide) 8mg/2.5mg DIN 02321653 PMS-amlodipine 2.5mg DIN 02295148 Special Authorization Coverage criteria can be viewed at http://www.health.gov.nl.ca/health/nlpdp/sadsearch.asp The following medications are now being considered under Special Authorization for Foundation, Access, 65Plus and Assurance Plans: Oxycontin 15mg DIN 02323192 Persistent Pain Oxycontin 30mg DIN 02323206 Oxycontin 60mg DIN 02323214 Rebif 66ug/1.5ml multidose cartridge DIN 02318253 Multiple Sclerosis Rebif 32ug/1.5ml multidose cartridge DIN 02318261 Betaseron Initiation Pack DIN 02169649 Multiple Sclerosis Prezista 75mg DIN 02338432 Prezista 300mg DIN 02284057 Prezista 400mg DIN 02324016 Prezista 600mg DIN 02324024 Pediatric HIV-1 Orencia 250mg vial DIN 02282097 Rheumatoid Arthritis (New Criteria) Simponi 50mg/0.5ml disposable syringe DIN 02324776 Simponi 50mg/0.5ml injector pen DIN 02324784 Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis The Common Drug Review (CDR) reviews new drugs and provides an evidence-based formulary listing recommendation, made by the Canadian Expert Drug Advisory Committee (CEDAC), on behalf of participating publicly-funded drug plans. Reviews for the following products were completed by the Common Drug Review and coverage was not recommended. As such, these products will not be considered for coverage under the NLPDP. CEDAC recommendations can be viewed at http://www.cadth.ca/index.php/en/cdr/committees/cedac Isentress 400mg DIN 02301881 Treatment-naïve HIV-1 Multaq 400mg DIN 02330989 Nplate 250mcg DIN 02322854, 500mcg DIN 02322862 Cimzia 200mg/ml DIN 02331675 Rhuematoid Arthritis Jurnista 4mg DIN 02337266, 8mg DIN 02337274, 16mg DIN 02337282, 32mg DIN 02337290 Lotemax 0.5% Eye Drops DIN 02321114 Onglyza 5mg DIN 02333554 The Atlantic Common Drug Review (ACDR) is a regional review process that provides evidencebased recommendations for coverage of new indications and line extensions for existing medications. Drug evaluation summaries are prepared by independent reviewers based on the manufacturer’s drug submission and a systematic literature search. The drug evaluation summary is presented to the Atlantic Expert Advisory Committee who recommends the place in therapy. It is then up to each individual province to make a decision as to the coverage status. Reviews for the following products were completed by the ACDR and coverage was not recommended. As such, these products will not be considered for coverage under the NLPDP. Betaseron 0.3mg DIN 02169649 Clinically Isolated Syndrome (CIS) Niaspan 500mg DIN 02262347, 750mg DIN 02262355, 1000mg DIN 02262339
